Skip to main content

ENGLISH · EVIDENCE OVERVIEW

Vesugen
evidence profile

KED tripeptide / experimental cell signalling. This is a concise English overview, not a full translation. Read the evidence boundaries and original sources below; the detailed study and risk discussion remains available in Thai.

What do Class, Grade and Risk mean?

Vesugen: conceptual scientific illustration for Clinical / Endocrine Pharmacology
VISUAL GUIDE · Vesugen

Clinical / Endocrine Pharmacology

Category-level conceptual illustration, not a map of this molecule's receptor targets. It is not a treatment outcome and does not establish efficacy or safety.

QUICK ANSWER · AEO / GEO

Vesugen is KED, not KEDG or KEDW. Endothelial-cell, fibroblast and docking findings concern proliferation/differentiation markers. They do not establish prevention of stroke or heart attack, and human-derived cells are not human clinical trials.

01

ENTITY FACTS

What should readers identify first?

MOLECULEVesugen
PHARMACOLOGYKED tripeptide / experimental cell signalling
PRIMECORE CLASSC
EVIDENCE GRADEE
RESEARCH TOPICClinical / Endocrine Pharmacology
LAST REVIEWED2026-08-30

What remains unknown?

Insufficient data in the current dataset

What limits these conclusions?

English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty.

Read original excerpts (Thai / mixed language)
  • การเปลี่ยน marker ของเซลล์หลอดเลือดไม่เท่ากับลดหัวใจวายหรืออัมพาต และไม่เท่ากับยาลดความดัน

This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.

02

EVIDENCE BOUNDARY

What this overview does not establish

  • An evidence grade does not rank this molecule against another treatment.
  • A molecule name does not establish the identity, purity or regulatory status of a product.
  • Animal, cell or biomarker findings do not automatically establish human clinical benefit.
  • Approval in one country or indication does not transfer globally.

Where can I check the evidence?

Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.

  1. Endothelial cultures and docking · PMID 25051766
  2. Differentiation markers · PMID 22808515
03

FAQ · ANSWER ENGINE

Frequently asked questions

What is Vesugen?

Vesugen is described pharmacologically as KED tripeptide / experimental cell signalling. Vesugen is KED, not KEDG or KEDW. Endothelial-cell, fibroblast and docking findings concern proliferation/differentiation markers. They do not establish prevention of stroke or heart attack, and human-derived cells are not human clinical trials.

Does Vesugen have strong evidence?

PrimeCoreBio records Evidence Grade E. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.

Is Vesugen approved everywhere?

No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.

Medical Disclaimer

Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.

Contact PrimeCoreBio

Choose a contact channel

General information only · No sales or medical advice